Major Pharmaceutical Companies Infuse Needed Capital Into Gene Therapy Research

Sidebar: Major Pharmaceutical Companies Are Diving Into the Gene Therapy Pool As gene therapy enters its sixth year of high-visibility research, major drug companies are buying in, helping lay the technology's foundation and launching clinical trials. More than 100 gene therapy trials-most privately funded-are under way. And while the field's ultimate success is still quite uncertain, one thing is clear: There is a lot of science to be done and research opportunities to be pursued. ACADEMIA, I

Kathryn Brown
Nov 12, 1995
Sidebar: Major Pharmaceutical Companies Are Diving Into the Gene Therapy Pool

As gene therapy enters its sixth year of high-visibility research, major drug companies are buying in, helping lay the technology's foundation and launching clinical trials. More than 100 gene therapy trials-most privately funded-are under way. And while the field's ultimate success is still quite uncertain, one thing is clear: There is a lot of science to be done and research opportunities to be pursued.

Jack Roth ACADEMIA, INDUSTRY UNITE: Jack Roth of U. Texas M.D. Anderson Cancer Center lauds drug firms' investment.


"It seems like there is a new company announcing a gene therapy project every week," says James Barrett, chief executive officer of Genetic Therapy Inc. (GTI), a publicly held biotechnology company in Gaithersburg, Md. "There is a whole wealth of opportunity for scientists."

James Barrett BUSTLE: James Barrett notes that gene therapy provides "a whole wealth of opportunity...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?